Pfizer says its COVID-19 vaccine safe and 95% effective; to seek emergency use approval 'in days'
The company didn’t disclose safety details but said no serious side effects have been reported, with the most common problem being fatigue after the second vaccine dose, affecting about four percent of participants
Pfizer says that more interim results from its ongoing coronavirus vaccine study suggest the shots are 95 percent effective and that the vaccine protects older people most at risk of dying from COVID-19.
The announcement, just a week after Pfizer first revealed promising preliminary results, comes as the company is preparing within days to formally ask US regulators to allow emergency use of the vaccine.
Pfizer initially had estimated its vaccine, developed with German partner BioNTech, was more than 90 percent effective after 94 infections had been counted.
With Wednesday’s announcement, the company now has accumulated 170 infections in the study: and said only eight of them occurred in volunteers who got the actual vaccine rather than a dummy shot.
One of those eight developed severe disease, the company said.
The company has not yet released detailed data on its study, and results have not been analysed by independent experts.
Pfizer said its vaccine was more than 94 percent effective in adults over age 65, though it is not clear how the company determined effectiveness in older adults, with only eight infections in the vaccinated group to analyze and no breakdown provided of those people’s ages.
Earlier this week Moderna, Inc. announced that its experimental vaccine appears to be 94.5 percent effective after an interim analysis of its late-stage study.
Pfizer says it now has the data on the vaccine’s safety needed to seek emergency authorisation from the Food and Drug Administration.
The company didn’t disclose safety details but said no serious vaccine side effects have been reported, with the most common problem being fatigue after the second vaccine dose, affecting about four percent of participants.
The study has enrolled nearly 44,000 people in the US and five other countries. The trial will continue to collect safety and efficacy data on volunteers for two more years.
Pfizer and BioNTech said they expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses in 2021.
US officials have said they hope to have about 20 million vaccine doses each from Moderna and Pfizer available for distribution in late December. The first shots will be offered to vulnerable groups like medical and nursing home workers, and people with serious health conditions.
The health ministry informed that the active cases stand at 0.04 per cent of the total coronavirus infections in the country
COVID-19 update: India reports 2,841 new cases, nine deaths in last 24 hours, active cases dip to 18,604
The fresh COVID-19 infections reported on Friday were marginally higher than 2,827 cases logged on Thursday. The daily positivity rate was recorded at 0.58 per cent, while the weekly positivity rate was 0.69 per cent
On Wednesday, Chinese capital Beijing recorded just 51 local virus infections including asymptomatic ones, while Shanghai reported nearly 5,000, a downward trend as the city loosens some restrictions